08:50 AM EDT, 04/06/2026 (MT Newswires) -- Stereotaxis ( STXS ) said Monday it obtained clearance for its Synchrony system from the US Food and Drug Administration.

The system is designed to modernize the interventional catheter lab, consolidating the viewing and control of all systems in the lab, the company said.

Stereotaxis ( STXS ) also said it is reiterating its 2026 revenue guidance of more than $3 million from Synchrony systems placed independent of robotic systems.